Atlanta—Therapeutic advances in recent years have beaten back and even defeated hematologic cancers in many patients, yet oncologists note that poor prognoses and cancer death rates remain significant. At the 49th Annual Meeting of the American Society of Hematology, held here in December, researchers discussed some of the latest efforts to advance the treatment of hematologic cancers, including Hodgkin and non-Hodgkin lymphomas, leukemia, and multiple myeloma.
Hampton T. Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies. JAMA. 2008;299(5):510-512. doi:10.1001/jama.299.5.510